NZ754922A - Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof - Google Patents

Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Info

Publication number
NZ754922A
NZ754922A NZ754922A NZ75492218A NZ754922A NZ 754922 A NZ754922 A NZ 754922A NZ 754922 A NZ754922 A NZ 754922A NZ 75492218 A NZ75492218 A NZ 75492218A NZ 754922 A NZ754922 A NZ 754922A
Authority
NZ
New Zealand
Prior art keywords
kinase inhibitors
compounds
pharmaceutical use
janus kinase
novel amino
Prior art date
Application number
NZ754922A
Other languages
English (en)
Inventor
Lars Rasmussen
Jens Larsen
Mogens Larsen
Andreas Ritzen
Tine Marianne Duus
Original Assignee
Aqilion Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion Ab filed Critical Aqilion Ab
Publication of NZ754922A publication Critical patent/NZ754922A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ754922A 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof NZ754922A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
NZ754922A true NZ754922A (en) 2025-11-28

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754922A NZ754922A (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Country Status (26)

Country Link
US (1) US10703751B2 (OSRAM)
EP (1) EP3568396B1 (OSRAM)
JP (1) JP7009504B2 (OSRAM)
KR (1) KR102548543B1 (OSRAM)
CN (1) CN110167938B (OSRAM)
AU (1) AU2018208516B2 (OSRAM)
CA (1) CA3045567A1 (OSRAM)
CY (1) CY1123864T1 (OSRAM)
DK (1) DK3568396T3 (OSRAM)
ES (1) ES2846741T3 (OSRAM)
HR (1) HRP20210095T1 (OSRAM)
HU (1) HUE052720T2 (OSRAM)
IL (1) IL267829B (OSRAM)
LT (1) LT3568396T (OSRAM)
MX (1) MX389378B (OSRAM)
MY (1) MY195576A (OSRAM)
NZ (1) NZ754922A (OSRAM)
PL (1) PL3568396T3 (OSRAM)
PT (1) PT3568396T (OSRAM)
RS (1) RS61317B1 (OSRAM)
RU (1) RU2019125177A (OSRAM)
SI (1) SI3568396T1 (OSRAM)
TW (1) TWI760419B (OSRAM)
UA (1) UA123972C2 (OSRAM)
WO (1) WO2018130563A1 (OSRAM)
ZA (1) ZA201904190B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PL3555097T3 (pl) 2016-12-16 2022-10-17 Janssen Pharmaceutica Nv Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP7345220B2 (ja) * 2019-08-30 2023-09-15 ティーエスディー ライフ サイエンス カンパニー リミテッド イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物
BR112023018286A2 (pt) 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389527B2 (en) * 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
EP2523957A1 (en) * 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
RU2013109143A (ru) * 2010-08-05 2014-09-10 Амджен Инк. Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
UY34616A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
WO2014081718A1 (en) * 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN104098563A (zh) * 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
SG11201609016VA (en) * 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
EA201990523A1 (ru) * 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Also Published As

Publication number Publication date
TW201829407A (zh) 2018-08-16
RU2019125177A3 (OSRAM) 2021-05-11
AU2018208516A1 (en) 2019-07-11
KR102548543B1 (ko) 2023-06-29
EP3568396B1 (en) 2020-11-11
CA3045567A1 (en) 2018-07-19
RU2019125177A (ru) 2021-02-15
CN110167938B (zh) 2024-06-14
EP3568396A1 (en) 2019-11-20
JP7009504B2 (ja) 2022-01-25
JP2020504186A (ja) 2020-02-06
ZA201904190B (en) 2020-10-28
HUE052720T2 (hu) 2021-05-28
TWI760419B (zh) 2022-04-11
CN110167938A (zh) 2019-08-23
ES2846741T3 (es) 2021-07-29
IL267829A (en) 2019-09-26
KR20190103231A (ko) 2019-09-04
BR112019014191A2 (pt) 2020-02-11
IL267829B (en) 2022-02-01
RS61317B1 (sr) 2021-02-26
WO2018130563A1 (en) 2018-07-19
SI3568396T1 (sl) 2021-04-30
PT3568396T (pt) 2021-02-09
MX389378B (es) 2025-03-20
US10703751B2 (en) 2020-07-07
US20190367512A1 (en) 2019-12-05
UA123972C2 (uk) 2021-06-30
CY1123864T1 (el) 2022-05-27
AU2018208516B2 (en) 2021-07-08
MY195576A (en) 2023-02-02
LT3568396T (lt) 2021-02-10
MX2019008331A (es) 2020-01-14
HRP20210095T1 (hr) 2021-03-05
DK3568396T3 (da) 2021-01-18
PL3568396T3 (pl) 2021-05-31

Similar Documents

Publication Publication Date Title
NZ754922A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
NZ777871A (en) Small molecule modulators of il-17
PH12020551305A1 (en) Pharmaceutical Compounds
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
CR20230215A (es) Compuestos de pirimidina, composiciones y aplicaciones médicas de esta
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AQILION AB, SE

Effective date: 20221214